Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7672741 | 0.81 | MEN1 (0.50) | MEN1KMT2APOLBKDM4EHSD17B10 | |
| SCHEMBL15678813 | 0.80 | KDM4E (0.79) | MEN1KMT2APOLBKDM4EHSD17B10 | |
| SCHEMBL14478875 | 0.80 | KDM4E (1.00) | MEN1KMT2APOLBKDM4EHSD17B10 | |
| SCHEMBL13402249 | 0.79 | KDM4E (1.00) | MEN1KMT2APOLBKDM4EHSD17B10 | |
| SCHEMBL12691232 | 0.77 | KDM4E (0.59) | MEN1KMT2APOLBKDM4EHSD17B10 | |
| SCHEMBL18324078 | 0.76 | TNKS2 (0.52) | MEN1KMT2APOLBKDM4EHSD17B10 | |
| SCHEMBL5626972 | 0.74 | PARP1 (0.56) | MEN1KMT2APOLBKDM4EHSD17B10 | |
| SCHEMBL541947 | 0.73 | MEN1 (0.49) | MEN1KMT2APOLBKDM4EHSD17B10 | |
| SCHEMBL30209785 | 0.73 | MEN1 (0.49) | MEN1KMT2APOLBKDM4EHSD17B10 | |
| SCHEMBL23175219 | 0.71 | PARP1 (0.57) | MEN1KMT2APOLBKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108774189-B | Oxazine phenyl ether derivative and preparation method thereof | 安徽师范大学 | 2022-04-19 | — | — | CN | claimed |
| US-20040043987-A1 | Novel compounds and their use as positive AMPA receptor modulators | NEUROSEARCH A/S. | 2004-03-04 | — | — | US | claimed |
| CN-1293665-A | New compounds and their use as positive AMPA receptor modulators | NEUROSEARCH AS (DK) | 2001-05-02 | — | — | CN | claimed |
| EP-1071426-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2001-01-31 | — | — | EP | claimed |
| WO-1999042456-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-08-26 | — | — | WO | claimed |
| CN-108774189-B | Oxazine phenyl ether derivative and preparation method thereof | 安徽师范大学 | 2022-04-19 | — | — | CN | disclosed |
| US-7235548-B2 | Compounds and their use as positive AMPA receptor modulators | NEUROSEARCH A/S (DK) | 2007-06-26 | — | — | US | disclosed |
| US-6943159-B1 | Compounds and their use as positive AMPA receptor modulators | NEUROSEARCH A/S (DK) | 2005-09-13 | — | — | US | disclosed |
| US-20040043987-A1 | Novel compounds and their use as positive AMPA receptor modulators | NEUROSEARCH A/S. | 2004-03-04 | — | — | US | disclosed |
| CN-1293665-A | New compounds and their use as positive AMPA receptor modulators | NEUROSEARCH AS (DK) | 2001-05-02 | — | — | CN | disclosed |
| EP-1071426-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999042456-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-08-26 | — | — | WO | disclosed |
| EP-0566018-B1 | Benzoxazinone and benzothiazinone derivatives endowed with cardiovascular activity | ITALFARMACO SPA (IT) | 1998-08-05 | — | — | EP | disclosed |
| US-5480882-A | Benzoxazinone and benzothiazinone derivatives having cardiovascular activity | ITALFARMACO S.P.A. (IT) | 1996-01-02 | — | — | US | disclosed |
| EP-0490183-B1 | Benzoxazinone and benzothiazinone derivatives endowed with cardiovascular activity | ITALFARMACO SPA (IT) | 1995-04-19 | — | — | EP | disclosed |
| EP-0566018-A2 | Benzoxazinone and benzothiazinone derivatives endowed with cardiovascular activity | ITALFARMACO S.p.A. (IT) | 1993-10-20 | — | — | EP | disclosed |
| US-5189034-A | Vasodilating, antianginal agents | ITALFARMACO S.P.A. (IT) | 1993-02-23 | — | — | US | disclosed |
| EP-0490183-A1 | Benzoxazinone and benzothiazinone derivatives endowed with cardiovascular activity | ITALFARMACO S.p.A. (IT) | 1992-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043987-A1 | Novel compounds and their use as positive AMPA receptor modulators | GRIK4, GRIA4, GRM2 | MEN1 4649/4885KMT2A 869/4885POLB 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.